Lasers, Lungs & Leapfrogs: Innovation Sparks Market Moves as Healthcare Stocks Surge

September 2, 2025

DENVER, Colo., Sep 02, 2025 (247marketnews.com)- Wall Street is kicking off September with a sharp focus on healthcare innovation, where breakthroughs in dermatology, respiratory disease, and oncology are capturing investor attention and analyst upgrades.

STRATA Skin Sciences (NASDAQ:SSKN) is asserting its intellectual property moat with three critical patents that grant market exclusivity for its XTRAC Excimer Laser when combined with JAK inhibitors, systemic, and biologic drugs. The Company is actively working with CMS to implement temporary CPT code expansions as early as 2026, significantly broadening its reimbursable use cases beyond psoriasis to include vitiligo, alopecia areata, and atopic dermatitis.

STRATA CEO Dr. Dolev Rafaeli noted that the IP foundation is essential to protecting years of investment and enabling a scalable entry into combination therapy markets. These developments position SSKN at the forefront of personalized, integrative dermatologic care, with strategic litigation also underway to defend its IP assets.

With an expanded addressable market and strong IP defense, SSKN may attract fresh institutional interest ahead of 2026 reimbursement changes.

United Therapeutics (NASDAQ:UTHR) announced that its TETON-2 pivotal study for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) met its primary and multiple secondary endpoints, showing a statistically significant improvement in lung function (FVC) compared to placebo.

The data includes a 95.6 mL improvement in FVC at 52 weeks (p < 0.0001), with benefits across all patient subgroups. The company aims to file a supplemental NDA to expand Tyvaso’s indication and will present detailed results at the European Respiratory Society Congress in Amsterdam on September 28.

With IPF representing a high-unmet-need market, UTHR is well-positioned to extend Tyvaso’s commercial potential. Shares are trading higher pre-market on optimism for regulatory acceleration.

LIXTE Biotechnology (NASDAQ:LIXT) is gaining attention following coverage in Trends in Cancer spotlighting a global meeting on “hyperactivation therapy”, a bold strategy that forces tumor cells into lethal overdrive. LIXTE’s LB-100, a first-in-class PP2A inhibitor, was a highlight of the event and is being studied for its dual action: promoting immune visibility and driving oncogenic stress.

With increasing scientific validation and its leadership role at the conference, LIXTE is carving out a niche in a disruptive oncology model that could redefine cancer therapeutics.

MannKind’s (NASDAQ:MNKD) CEO and CFO are set to deliver updates at four major healthcare conferences this month, including Wells Fargo, Cantor, H.C. Wainwright, and Morgan Stanley. With strong momentum behind its inhalable drug platform and potential partnerships, investors are watching for clinical or commercial catalysts during this roadshow blitz. First appearance- Wednesday, September 3 @ 4:30 p.m. ET (Wells Fargo Healthcare Conference).

Momentum Movers to Watch

Several healthcare small caps are showing notable early strength:

Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LIXT, SSKN, UTHR, MKND, CARM, MLYS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.